[ad_1] UCB will contribute 14 presentations, including an oral presentation, selected to feature across the AANEM and MGFA meeting, emphasizing UCB’s leadership in neuromuscular research Presentations showcase new data for UCB’s gMG treatments, including post hoc […]
[ad_1] Clinically meaningful improvements observed with BIMZELX over one year of treatment were maintained up to two years (Week 96) At Week 96, over eight in 10 patients treated with BIMZELX achieved HiSCR50, over seven […]
[ad_1] New data presented at the 15th European Epilepsy Congress highlight lengthy delays in Lennox-Gastaut syndrome (LGS) diagnosis in Europe and significant disease burden from both seizure and non-seizure impairments[1] LGS is a severe childhood-onset developmental and […]
[ad_1] The inaugural UCB Hidradenitis Suppurativa (HS) Summit will bring people living with HS, caregivers, advocacy leaders, and invited healthcare providers together on UCB’s Atlanta campus to advance understanding of the HS treatment journey and […]
